JP2017536804A5 - - Google Patents

Download PDF

Info

Publication number
JP2017536804A5
JP2017536804A5 JP2017517301A JP2017517301A JP2017536804A5 JP 2017536804 A5 JP2017536804 A5 JP 2017536804A5 JP 2017517301 A JP2017517301 A JP 2017517301A JP 2017517301 A JP2017517301 A JP 2017517301A JP 2017536804 A5 JP2017536804 A5 JP 2017536804A5
Authority
JP
Japan
Prior art keywords
influenza
virus
amino acid
biologically active
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017517301A
Other languages
English (en)
Japanese (ja)
Other versions
JP6953308B2 (ja
JP2017536804A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/053385 external-priority patent/WO2016054309A1/en
Publication of JP2017536804A publication Critical patent/JP2017536804A/ja
Publication of JP2017536804A5 publication Critical patent/JP2017536804A5/ja
Application granted granted Critical
Publication of JP6953308B2 publication Critical patent/JP6953308B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017517301A 2014-10-02 2015-10-01 インフルエンザa型ウイルスバリアント Expired - Fee Related JP6953308B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462058961P 2014-10-02 2014-10-02
US62/058,961 2014-10-02
PCT/US2015/053385 WO2016054309A1 (en) 2014-10-02 2015-10-01 Influenza a virus variants

Publications (3)

Publication Number Publication Date
JP2017536804A JP2017536804A (ja) 2017-12-14
JP2017536804A5 true JP2017536804A5 (enExample) 2018-11-08
JP6953308B2 JP6953308B2 (ja) 2021-10-27

Family

ID=54293398

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017517301A Expired - Fee Related JP6953308B2 (ja) 2014-10-02 2015-10-01 インフルエンザa型ウイルスバリアント

Country Status (11)

Country Link
US (1) US10801076B2 (enExample)
EP (1) EP3201220A1 (enExample)
JP (1) JP6953308B2 (enExample)
KR (1) KR20170063944A (enExample)
CN (1) CN107002086B (enExample)
AU (1) AU2015325012B2 (enExample)
BR (1) BR112017006680A2 (enExample)
CA (1) CA2963070A1 (enExample)
MA (1) MA40772A (enExample)
RU (1) RU2748618C2 (enExample)
WO (1) WO2016054309A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010262905B2 (en) 2009-06-17 2015-04-16 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
EP3068782B1 (en) 2013-11-13 2018-05-23 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
ES2741444T3 (es) 2013-11-13 2020-02-11 Vertex Pharma Inhibidores de la replicación de virus de la gripe
MA40773A (fr) * 2014-10-02 2017-08-08 Vertex Pharma Variants du virus influenza a
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
WO2016183116A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
CA3094588A1 (en) * 2018-04-06 2019-10-10 Janssen Pharmaceuticals, Inc. Isothermal reactive crystallisation process for the preparation of a crystalline form of pimodivir hydrochloride hemihydrate
WO2020256820A1 (en) * 2019-06-20 2020-12-24 Janssen Pharmaceuticals, Inc. Formulations of azaindole compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843701A (en) 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
DE69739163D1 (de) 1996-10-17 2009-01-22 Mitsubishi Chem Corp Molekül, welches Genotyp und Phänotyp zusammenführt und dessen Anwendungen
PT971946E (pt) 1997-01-21 2006-11-30 Gen Hospital Corp Selecção de proteínas utilizando fusões arn-proteína
DE60137345D1 (de) * 2000-04-28 2009-02-26 St Jude Childrens Res Hospital Dna-transfektionssystem zur erzeugung von infektiösen negativsträngigen rna virus
CA2456292A1 (en) 2001-08-14 2003-02-27 Toyama Chemical Co., Ltd. Novel virus growth inhibitor and/or virucidal method, and novel pyrazine nucleotide or pirazine nucleoside analog
WO2005095400A1 (en) 2004-03-30 2005-10-13 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of jak and other protein kinases
WO2006050076A1 (en) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
FI20060200A0 (fi) * 2005-04-20 2006-02-27 Glykos Finland Oy Menetelmä ihmisen influenssaviruksen sialihahappositoumisspesifisyyden analysoimiseksi
PL1896470T3 (pl) 2005-05-16 2011-03-31 Irm Llc Pochodne pirolopirydynowe jako inhibitory kinazy białkowej
KR20080047355A (ko) * 2005-07-06 2008-05-28 바이오칩 이노베이션즈 피티와이 리미티드 표적 핵산 서열 분석 방법 및 키트
KR100708593B1 (ko) 2006-03-23 2007-04-18 주식회사 고려비엔피 발육란 생산성이 우수한 저병원성 h9n2 아형 조류인플루엔자 바이러스
WO2009125395A1 (en) * 2008-04-09 2009-10-15 Technion Research & Development Foundation Ltd. Anti influenza antibodies and uses thereof
AU2010262905B2 (en) 2009-06-17 2015-04-16 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
UA118010C2 (uk) * 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
MA40773A (fr) * 2014-10-02 2017-08-08 Vertex Pharma Variants du virus influenza a

Similar Documents

Publication Publication Date Title
JP2017536804A5 (enExample)
JP2017537605A5 (enExample)
Álvarez-Buylla et al. Identification of Acinetobacter species: is Bruker biotyper MALDI-TOF mass spectrometry a good alternative to molecular techniques?
Okomo‐Adhiambo et al. Assays for monitoring susceptibility of influenza viruses to neuraminidase inhibitors
Akhmetova et al. Mutations in the pncA and rpsA genes among 77 Mycobacterium tuberculosis isolates in Kazakhstan
EP2630239B1 (en) Kit for detecting bovine leukemia virus (blv), and use thereof
RU2017114675A (ru) Варианты вируса гриппа a
US20210292820A1 (en) Compositions and methods for detecting and treating sars-cov-2
Cotroneo et al. Lung expression of genes putatively involved in SARS-CoV-2 infection is modulated in cis by germline variants
Sun et al. Molecular typing of epizootic hemorrhagic disease virus serotypes by one-step multiplex RT-PCR
US20200216903A1 (en) Mitochondrial Disease Genetic Diagnostics
Fidler et al. Circulating microRNA sequencing revealed miRNome patterns in hematology and oncology patients aiding the prognosis of invasive aspergillosis
JPWO2020032228A5 (enExample)
CN104313123B (zh) 一种结核分枝杆菌四种一线药物耐药基因特异片段组合及其应用
CN103540676B (zh) 一种检测线粒体基因1555位a-g与1494位c-t突变的试剂盒
JP7084034B2 (ja) 神経芽腫の微小残存病変を評価するために用いられる試薬、およびそれを用いた生体試料の分析方法
KR20230117152A (ko) 코로나바이러스 감염 발생 위험이 증가한 대상체의 식별 및 이의 치료 방법
RU2550257C2 (ru) СПОСОБ ДИФФЕРЕНЦИАЦИИ ТИПИЧНЫХ И АТИПИЧНЫХ ШТАММОВ Yersinia pestis СРЕДНЕВЕКОВОГО БИОВАРА МЕТОДОМ ПЦР С ГИБРИДИЗАЦИОННО-ФЛУОРЕСЦЕНТНЫМ УЧЕТОМ РЕЗУЛЬТАТОВ
CN116855637B (zh) 一种检测美洲鳗鲡腺瘤病毒的引物对和试剂盒
Minime-Lingoupou et al. Rapid identification of multidrug-resistant tuberculosis isolates in treatment failure or relapse patients in Bangui, Central African Republic
RU2762236C1 (ru) Набор синтетических олигонуклеотидных праймеров для получения полной нуклеотидной последовательности гена vp1 энтеровируса коксаки а10
Doumayrou et al. Mapping genetic determinants of viral traits with FST and quantitative trait locus (QTL) approaches
CN105316350B (zh) 结核分枝杆菌EmbB突变基因及其用途
JP4853898B2 (ja) Dna標準物質
Leisova‐Svobodova et al. Detection of Garlic Viruses Using SYBR Green Real‐time Reverse Transcription‐Polymerase Chain Reaction